Management of suspected opioid overdose with naloxone in out-of-hospital settings

Roger Chou, P. Todd Korthuis, Dennis McCarty, Phillip O. Coffin, Jessica C. Griffin, Cynthia Davis-O'Reilly, Sara Grusing, Mohamud Daya

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Background: Naloxone is effective for reversing opioid overdose, but optimal strategies for out-of-hospital use are uncertain. Purpose: To synthesize evidence on 1) the effects of naloxone route of administration and dosing for suspected opioid overdose in out-of-hospital settings on mortality, reversal of overdose, and harms, and 2) the need for transport to a health care facility after reversal of overdose with naloxone. Data Sources: Ovid MEDLINE (1946 through September 2017), PsycINFO, Cochrane Central Register of Controlled Trials, CINAHL, U.S. Food and Drug Administration (FDA) materials, and reference lists. Study Selection: English-language cohort studies and randomized trials that compared different doses of naloxone, administration routes, or transport versus nontransport after reversal of overdose with naloxone. Main outcomes were mortality, reversal of overdose, recurrence of overdose, and harms. Data Extraction: Dual extraction and quality assessment of individual studies; consensus assessment of overall strength of evidence (SOE). Data Synthesis: Of 13 eligible studies, 3 randomized controlled trials and 4 cohort studies compared different administration routes. At the same dose (2 mg), 1 trial found similar efficacy between higher-concentration intranasal naloxone (2 mg/mL) and intramuscular naloxone, and 1 trial found that lowerconcentration intranasal naloxone (2 mg/5 mL) was less effective than intramuscular naloxone but was associated with decreased risk for agitation (low SOE). Evidence was insufficient to evaluate other comparisons of route of administration. Six uncontrolled studies reported low rates of death and serious adverse events (0% to 1.25%) in nontransported patients after successful naloxone treatment. Limitation: There were few studies, all had methodological limitations, and none evaluated FDA-Approved autoinjectors or highly concentrated intranasal formulations. Conclusion: Higher-concentration intranasal naloxone (2 mg/ mL) seems to have efficacy similar to that of intramuscular naloxone for reversal of opioid overdose, with no difference in adverse events. Nontransport after reversal of overdose with naloxone seems to be associated with a low rate of serious harms, but no study evaluated risks of transport versus nontransport. Primary Funding Source: Agency for Healthcare Research and Quality. (PROSPERO: CRD42016053891)

Original languageEnglish (US)
Pages (from-to)867-875
Number of pages9
JournalAnnals of internal medicine
Volume167
Issue number12
DOIs
StatePublished - Dec 19 2017

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Management of suspected opioid overdose with naloxone in out-of-hospital settings'. Together they form a unique fingerprint.

Cite this